BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22390890)

  • 1. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen.
    ten Dam K; de Groot IJ; Noordam C; van Alfen N; Hendriks JC; Sie LT
    Neuromuscul Disord; 2012 Jun; 22(6):500-4. PubMed ID: 22390890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
    Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
    Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
    J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy.
    Daftary AS; Crisanti M; Kalra M; Wong B; Amin R
    Pediatrics; 2007 Feb; 119(2):e320-4. PubMed ID: 17272595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prednisone treatment in Duchenne muscular dystrophy.
    Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
    Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel treatment regimen for Duchenne muscular dystrophy.
    Li M; Cai Y; Zhong M; Zou L; Gong C
    Neuroreport; 2013 Nov; 24(16):924-7. PubMed ID: 24045777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
    Connolly AM; Schierbecker J; Renna R; Florence J
    Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians].
    de Groot IJ
    Ned Tijdschr Geneeskd; 2006 Mar; 150(12):684-5. PubMed ID: 16613254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy.
    Straathof CS; Overweg-Plandsoen WC; van den Burg GJ; van der Kooi AJ; Verschuuren JJ; de Groot IJ
    J Neurol; 2009 May; 256(5):768-73. PubMed ID: 19306039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy.
    Moxley RT; Pandya S
    Neurology; 2011 Aug; 77(5):416-7. PubMed ID: 21753162
    [No Abstract]   [Full Text] [Related]  

  • 15. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
    Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
    Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.
    Lai HC; FitzSimmons SC; Allen DB; Kosorok MR; Rosenstein BJ; Campbell PW; Farrell PM
    N Engl J Med; 2000 Mar; 342(12):851-9. PubMed ID: 10727589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
    Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
    Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.